A Continuum of Care for Metastatic CRC

Video

A Continuum of Care for Metastatic CRC

February 2013

  • A 53-year old Caucasian man presented to his gastroenterologist complaining of rectal bleeding and abdominal tenderness
  • PMH includes hypertension, well-controlled on a beta-blocker
  • Family history; mother died from breast cancer
  • He underwent colonoscopy with biopsy
    • Pathology results confirmed poorly-differentiated adenocarcinoma
    • Genetic testing was positive forKRASexon 2 codon 12 mutation
  • CT scan of the abdomen, pelvis, and chest showed multiple liver lesions and a large nodule in the right lower pulmonary lobe.
  • Diagnosis: Adenocarcinoma of the colon; staging, T4N0M1
  • The patient was started on FOLFOX and bevacizumab, therapy is well-tolerated
  • The second follow-up scan showed a marked decrease in volume of the primary tumor, two of the liver lesions, and the lung lesion.

March 2014

  • The patient complains of intermittent shortness of breath but continues his normal activities
  • Imaging shows slow but steady progression in the plural lesion
  • Bevacizumab therapy was continued; the patient was also started on FOLFIRI
  • Follow-up imaging shows continued regression of the lung lesion; patient continues to tolerate therapy with management of gastrointestinal distress

February 2017

  • The patient complains of abdominal fullness, nausea, and constipation
  • He continues to work full-time but feels sluggish
  • MRI indicated diffuse metastatic disease in the peritoneum, consistent with carcinomatosis
  • The patient was started on regorafenib 80 mg, with a plan to gradually increase to 160 mg if tolerated
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content